Evidence map›Paper›PMID 42204860›Full record

ReviewThe Annals of pharmacotherapy2026

Zoliflodacin for Urogenital Gonorrhea Infections.

Joshua T Wollen, Abdulwhab Shremo Msdi, Taryn Eubank

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Annals of pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joshua T WollenDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA.ORCID 0000-0003-3944-4875
Abdulwhab Shremo MsdiDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA.ORCID 0009-0009-1582-0611
Taryn EubankDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA.ORCID 0000-0002-6645-406X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo review the pharmacology, efficacy, and safety of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea due to DATA SOURCES AND EXTRACTION: A literature search was conducted in Scopus, Web of Science, PubMed Central, Gale Academic FileOne, MEDLINE, Journals@Ovid, and Science Direct databases for all articles relevant to zoliflodacin from inception through February 12, 2026. DATA SYNTHESIS: Preclinical, pharmacokinetic, and clinical trial data have demonstrated that zoliflodacin is effective against multidrug-resistant (MDR)

conclusionZoliflodacin is a novel, first-in-class spiropyrimidinetrione antibiotic for the treatment of uncomplicated urogenital gonorrhea that is efficacious and provides a novel option for MDR

Indexed as

Anti-Bacterial AgentsBarbituratesGonorrheaIsoxazolesAnimalsDrug Resistance, Multiple, BacterialHumansMorpholinesNeisseria gonorrhoeaeOxazolidinonesSpiro CompoundsAnti-Bacterial AgentsBarbituratesIsoxazolesMorpholinesOxazolidinonesSpiro Compoundszoliflodacinantibioticfluoroquinolonenovel agentssexually transmitted infectionsSTI

Identifiers

PMID42204860
PMCPMC13678065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.